Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Stage, Randomized, Double-Blind, Dose-Ranging, Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 on HSV Shedding in Adults With Recurrent Genital HSV-2 Infection.

NCT03595995 is registered in ClinicalTrials.gov with United BioPharma as lead sponsor.

NCT NCT03595995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03595995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Stage, Randomized, Double-Blind, Dose-Ranging, Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 on HSV Shedding in Adults With Recurrent Genital HSV-2 Infection.
Lead sponsor
United BioPharma
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2023
Completion date
June 30, 2024
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

genital herpes